, Volume 38, Supplement 2, pp 1–8 | Cite as

Profile of an Ideal Antianginal Agent

  • Eliot J. Lazar
  • William H. Frishman
Section 1: The Profile of Epanolol: A New Antianginal Agent


Many antianginal agents are available for the treatment of coronary artery disease. These agents act by influencing the determinants of myocardial oxygen supply and demand. The 3 main classes of agents are the nitrates, β-adrenergic blocking agents and the calcium entry blockers. Agents from all 3 classes have shown efficacy in treating both symptomatic and asymptomatic myocardial ischaemia. However, some patients cannot be treated with these agents because of side effects or contraindications. An ideal antianginal drug should effectively treat both angina and silent ischaemia. Additionally, it should be free of side effects, allow for maintenance of physical performance and be metabolically neutral. New agents are being developed which strive for this goal.


Angina Pectoris Myocardial Blood Flow Coronary Blood Flow American Heart Journal Chronic Stable Angina 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Abrams J. Nitrate tolerance and dependence. American Heart Journal 99: 113–123, 1980PubMedCrossRefGoogle Scholar
  2. Abrams J. Use of nitroglycerin and long acting nitrates. In Weiner DA, Frishman WH (Eds) Therapy of angina pectoris: a comprehensive guide for the clinician, pp. 53–81, Marcel Dekker, 1986Google Scholar
  3. Abrams J. Nitrates. Medical Clinics of North America 72: 1–35, 1988PubMedGoogle Scholar
  4. Abrams J, Raizada V, Peake G, Schroeder K, Gerety B. Prostaglandins do not modulate the effects of nitroglycerin. Journal of Clinical Pharmacology 24: 414, 1984Google Scholar
  5. Alderman EL, Coltart DJ, Wettach GE, Harrison DC. Coronary artery syndromes after sudden propranolol withdrawal. Annals of Internal Medicine 81: 625–627, 1974PubMedGoogle Scholar
  6. Antman E, Muller J, Goldberg S, MacAlpin R, Rubenfire M, et al. Nifedipine therapy for coronary artery spasm. New England Journal of Medicine 302: 1269–1273, 1980PubMedCrossRefGoogle Scholar
  7. Armstrong PW, Moffat JA. Tolerance to organic nitrates: clinical and experimental perspectives. American Journal of Medicine 74: 73–84, 1983PubMedCrossRefGoogle Scholar
  8. Arsura E, Lichstein E, Guadagnino V, Nicchi V, Sanders M, et al. Methemoglobin levels produced by organic nitrates in patients with coronary artery disease. Journal of Clinical Pharmacology 24: 160–164, 1984PubMedGoogle Scholar
  9. Bala Subramanian V, Bowles MJ, Khurmi NS, et al. Rationale for the choice of calcium antagonists in chronic stable angina: an objective double-blind, placebo-controlled comparison of nifedipine and verapamil. American Journal of Cardiology 50: 1173–1179, 1982CrossRefGoogle Scholar
  10. Bardenheuer H, Schrader J. Supply-to-demand ratio for oxygen determines formation of adenosine by the heart. American Journal of Physiology 250: H173–H180, 1986PubMedGoogle Scholar
  11. Braunwald E, Sobel B. Coronary blood flow and myocardial ischemia. In Braunwald (Ed.) Heart disease: a textbook of cardiovascular medicine, pp. 1191–1221, WB Saunders & Co, 1988Google Scholar
  12. Brown BG, Bolson E, Petersen RB, Pierce CD, Dodge HT. The mechanisms of nitroglycerin action. Stenosis vasodilatation as a major component of drug response. Circulation 64: 1089–1097, 1981Google Scholar
  13. Brunton TL. On the use of nitrate of amyl in angina pectoris. Lancet 2: 97–98, 1867CrossRefGoogle Scholar
  14. Carvalho AC, Colman RW, Lees R. Platelet function in hyper-lipidemia. New England Journal of Medicine 290: 434, 1974PubMedCrossRefGoogle Scholar
  15. Cohn PF, Brown EJ, Swinford R, Atkins H. Effect of beta blockade on silent regional left ventricular wall motion abnormalities. American Journal of Cardiology 57: 521–526, 1986PubMedCrossRefGoogle Scholar
  16. Day JL, Metcalfe J, Simpson CN. Adrenergic mechanisms in control of plasma lipid concentrations. British Medical Journal 284: 1145–1148, 1982PubMedCrossRefGoogle Scholar
  17. Detar R, Bohr DF. Oxygen and vascular smooth muscle contraction. American Journal of Physiology 214: 241–244, 1968PubMedGoogle Scholar
  18. Egstrup K. Transient myocardial ischemia after abrupt withdrawal of antianginal therapy in chronic stable angina. American Journal of Cardiology 61: 1219–1222, 1988PubMedCrossRefGoogle Scholar
  19. Epstein SE, Braunwald E. Inhibition of the adrenergic nervous system in the treatment of angina pectoris. Medical Clinics of North America 52: 1031–1039, 1968PubMedGoogle Scholar
  20. Fox KM, Jonathan A, Selwyn AP. The use of propanolol and nifedipine in the medical management of angina pectoris. Clinical Cardiology 4: 125–129, 1981PubMedCrossRefGoogle Scholar
  21. Frishman WH. Beta-adrenoceptor antagonists. New drugs and new indications. New England Journal of Medicine 305: 500–506, 1981PubMedCrossRefGoogle Scholar
  22. Frishman WH. Multifactorial actions of beta adrenergic blocking drugs in ischemic heart disease: current concepts. Circulation 67 (Suppl. I): 111–118, 1983Google Scholar
  23. Frishman WH. Pharmacodynamic and pharmacokinetic principles. In Clinical pharmacology of the beta-adrenoceptor blocking drugs, pp. 13–26, Appleton-Century-Crofts, New Jersey, 1984Google Scholar
  24. Frishman WH. Pharmacology of the nitrates in angina pectoris. American Journal of Cardiology 56: 81–131, 1985CrossRefGoogle Scholar
  25. Frishman WH. Beta-adrenergic blockers. Medical Clinics of North America 72: 37–81, 1988PubMedGoogle Scholar
  26. Frishman WH, Silverman R. Clinical pharmacology of the new beta-adrenergic blocking drugs. Part 3. Comparative clinical experience and new therapeutic applications. American Heart Journal 98: 119–131, 1979PubMedCrossRefGoogle Scholar
  27. Frishman WH, Lazar EJ. New therapy update: labetalol. Cardiovascular Reviews and Reports 6: 117–118, 1985Google Scholar
  28. Frishman WH, Kafka KR. Antianginal agents. In Wang (Ed.) Practical drug therapy, pp. 55–84, Medstream Press, 1987Google Scholar
  29. Frishman WH, Weksler B, Christodoulou J, Smithen C, Killip T. Reversal of abnormal platelet aggregability and change in exercise tolerance in patients with angina pectoris following oral propranolol. Circulation 50: 887–896, 1974PubMedCrossRefGoogle Scholar
  30. Frishman WH, Christodoulou J, Weksler B, Smithen C, Killip T, et al. Abrupt propranolol withdrawal in angina pectoris: effects of platelet aggregation and exercise tolerance. American Heart Journal 95: 169–179, 1978PubMedCrossRefGoogle Scholar
  31. Frishman WH, Klein NA, Klein P, Strom JA, Tawil R, et al. Comparison of oral propranolol and verapamil for combined systemic hypertension and angina pectoris: a placebo-controlled, double-blind, randomized, crossover trial. American Journal of Cardiology 50: 1164–1172, 1982PubMedCrossRefGoogle Scholar
  32. Frishman WH, Kimmel B, Charlap S, Teicher M, Cinnamon J, et al. Diltiazem compared to nifedipine and combination treatment in patients with stable angina: effects on angina, exercise tolerance, and the ambulatory ECG. Circulation 77: 774–786, 1988PubMedCrossRefGoogle Scholar
  33. Gottlieb SO, Weisfewldt M, Ouyang P, Mellits ED, Gerstenblith G. Silent ischemia as a marker for early unfavorable outcomes in unstable angina. New England Journal of Medicine 314: 1214–1219, 1986PubMedCrossRefGoogle Scholar
  34. Gottlieb SO, Gottlieb SH, Achuff SC, Baumgartner R, Mellits ED, et al. Silent ischemia on Holter monitoring predicts mortality in high-risk postinfarction patients. Journal of the American Medical Association 259: 1030–1035, 1988PubMedCrossRefGoogle Scholar
  35. Greenberg H, Dwyer EM, Jameson AG, Pinkerneil BH. Effects of nitroglycerin on the major determinants of myocardial oxygen consumption. American Journal of Cardiology 36: 426–432, 1975PubMedCrossRefGoogle Scholar
  36. Harker LA, Ritchie JL. The role of platelets in acute vascular events. Circulation 62 (Suppl. V): V13–V18, 1980PubMedGoogle Scholar
  37. Hillis LD, Braunwald E. Myocardial ischemia. New England Journal of Medicine 296: 971–978, 1977PubMedCrossRefGoogle Scholar
  38. Ignarro LJ, Lippton H, Edwards JC, Baricos WH, Hyman AL, et al. Mechanism of vascular smooth muscle relaxation by organic nitrates, nitrites, nitroprusside and nitric oxide: evidence for the involvement of S-nitrosothiols as active intermediates. Journal of Pharmacology and Experimental Therapeutics 218: 739–749, 1981PubMedGoogle Scholar
  39. Johnson SM, Mauritson DR, Willerson JT, Hillis LD. A controlled trial of verapamil for Prinzmetal’s variant angina. New England Journal of Medicine 304: 862–866, 1981PubMedCrossRefGoogle Scholar
  40. Kannel WB, Gordon T. The Framingham study: an epidemiological investigation of cardiovascular disease, section 30. Some characteristics related to the incidence of cardiovascular disease and death: the Framingham Study 18 year followup, Washington D.C. Department of Health, Education and Welfare publication (NIH), pp. 74–559, 1974Google Scholar
  41. Keefe DL, Frishman WH. Clinical pharmacology of the calcium channel blocking drugs. In Packer MP, Frishman WH (Eds) Calcium channel antagonists in cardiovascular disease, pp.3–19, Appleton-Century-Crofts, New Jersey, 1984Google Scholar
  42. Khurmi NS, Bowles MJ, O’Hara MJ, Raftery EB. Effect of propranolol on indices of intermittent myocardial ischemia, assessed by exercise testing and ambulatory ST-segment monitoring. Clinical Cardiology 9: 391–397, 1986PubMedCrossRefGoogle Scholar
  43. Kirk ES, Sonnenblick EH. Newer concepts in the pathophysiology of ischemic heart disease. American Heart Journal 103: 756–767, 1982PubMedCrossRefGoogle Scholar
  44. Kostuk WJ, Pflugfelder P. Comparative effects of calcium-entry blocking drugs, beta-blocking drugs, and their combination in patients with chronic stable angina. Circulation 75 (Suppl. V): V114–V121, 1987PubMedGoogle Scholar
  45. Kwaan HC, Colwell JA, Cruz S, Suwanwela N, Dobbie JG, Increased platelet aggregation in diabetes mellitus. Journal of Laboratory Clinical Medicine 80: 236–246, 1972Google Scholar
  46. Levin RI, Jaffe EA, Weksler BB, Tack-Goldman K. Nitroglycerin stimulates synthesis of prostacyclin by cultured human endothelial cells. Journal of Clinical Investigation 67: 762–769, 1981PubMedCrossRefGoogle Scholar
  47. Lynch P, Dargie H, Krikler S, Krikler D. Objective assessment of antianginal treatment: a double-blind comparison of propanolol, nifedipine, and their combination. British Medical Journal 48: 184–187, 1980CrossRefGoogle Scholar
  48. Maseri A, Chierchia S. Coronary artery spasm: demonstration, definition, diagnosis and consequences. Progress in Cardiovascular Disease 25: 169–192, 1982CrossRefGoogle Scholar
  49. Miller RR, Olson HG, Amsterdam EA, Mason DT. Propanolol withdrawal rebound phenomenon: exacerbation of coronary events after abrupt cessation of anti-anginal therapy. New England Journal of Medicine 293: 416–418, 1975PubMedCrossRefGoogle Scholar
  50. Needleman P, Johnson EM. Mechanism of tolerance development to organic nitrates. Journal of Pharmacology and Experimental Therapeutics 184: 709–715, 1973PubMedGoogle Scholar
  51. Opie LH. Myocardial infarct size. Part 1. Basic considerations. American Heart Journal 100: 355–372, 1980PubMedCrossRefGoogle Scholar
  52. Parker JO, Fung HL. Transdermal nitroglycerin in angina pectoris. American Journal of Cardiology 54: 471–476, 1984PubMedCrossRefGoogle Scholar
  53. Parmley WW. The combination of beta-adrenergic blocking agents and nitrates in the treatment of stable angina pectoris. Cardiology Reviews and Reports 3: 1425, 1982Google Scholar
  54. Pasotti C, Capra A, Fiorella G, Vibelli C, Chierichetti SM. Effects of pindolol and metoprolol on plasma lipids and lipoproteins. British Journal of Clinical Pharmacology 13 (Suppl. 2): 435S–439S, 1982PubMedCrossRefGoogle Scholar
  55. Patterson RE, Jones-Collins BA, Aamodt R, Ro YM. Differences in collateral myocardial blood flow following gradual versus abrupt coronary occlusion. Cardiovascular Research 17: 207–213, 1983PubMedCrossRefGoogle Scholar
  56. Poplawski A, Skorolska M, Niewarowski S. Increased platelet adhesiveness in hypertensive cardiovascular disease. Journal of Atherosclerosis Research 8: 721–723, 1968PubMedCrossRefGoogle Scholar
  57. Przbojewski JZ, Heyns MH. Acute coronary vasospasm secondary to industrial nitroglycerin withdrawal. South African Medical Journal 63: 158–165, 1983Google Scholar
  58. Quyyumi AA, Wright C, Mockus L, Fox KM. Effect of partial agonist activity in beta blockers in severe angina pectoris: a double blind comparison of pindoloi and atenolol. British Medical Journal 289: 951–953, 1984PubMedCrossRefGoogle Scholar
  59. Roberts WC. Recent studies on the effects of beta blockers on blood lipid levels. American Heart Journal 117: 709–714, 1989PubMedCrossRefGoogle Scholar
  60. Rosenthal SJ, Ginsburg R, Lamb IH, Bairn DS, Schroeder JS. Efficacy of diltiazem for control of symptoms of coronary arterial spasm. American Journal of Cardiology 46: 1027–1032, 1980PubMedCrossRefGoogle Scholar
  61. Rubio R, Berne RM. Release of adenosine by the normal myocardium and its relationship to the regulation of coronary resistance. Circulation Research 25: 407–415, 1969PubMedCrossRefGoogle Scholar
  62. Rubio R, Berne R. Regulation of coronary blood flow. Progress in Cardiovascular Disease 18: 105–122, 1975CrossRefGoogle Scholar
  63. Rutherford JD, Braunwald E, Cohn PF. Chronic ischemic heart disease. In Braunwald (Ed.) Heart disease: a textbook of cardiovascular medicine, pp. 1314–1378, WB Saunders & Co, 1988Google Scholar
  64. Schang SJ, Pepine CJ. Transient asymptomatic ST-segment depression during daily activity. American Journal of Cardiology 39: 396–402, 1977PubMedCrossRefGoogle Scholar
  65. Schaper W. The physiology of the collateral circulation in the normal and hypoxic myocardium. Reviews of Physiology, Biochemistry and Pharmacology 63: 102–145, 1971Google Scholar
  66. Schiffl H, Weidmann P, Mordasini R, Riesen W, Bachmann C. Reversal of diuretic-induced increases in serum low-density lipoprotein cholesterol by the beta blocker pindolol. Metabolism 31: 411–415, 1982PubMedCrossRefGoogle Scholar
  67. Shell WF, Kivowitz CF, Rubins SB, See J. Mechanisms and therapy of silent myocardial ischemia: the effect of transdermal nitroglycerin. American Heart Journal 112: 222–229, 1986PubMedCrossRefGoogle Scholar
  68. Simons LA. Interrelations of lipids and lipoproteins with coronary artery disease mortality in 19 countries. American Journal of Cardiology 57: 5G-10G, 1986CrossRefGoogle Scholar
  69. Sonnenblick EH, Skelton CL. Myocardial energetics: basic principles and clinical implications. New England Journal of Medicine 285: 668–675, 1971PubMedCrossRefGoogle Scholar
  70. Sonnenblick EH, Rose J, Braunwald E. Oxygen consumption of the heart. Newer aspects of its multifactorial determination. American Journal of Cardiology 22: 328–336, 1968Google Scholar
  71. Sparks HV, Bardenheuer H. Regulation of adenosine formation by the heart. Circulation Research 58: 193–201, 1986PubMedCrossRefGoogle Scholar
  72. Van Brumelen. The relevance of intrinsic sympathomimetic activity for beta-blocker induced changes in plasma lipids. Journal of Cardiovascular Pharmacology 5: S51–S55, 1983CrossRefGoogle Scholar
  73. Vatner SF, Pagani M, Manders WT, Pasipoularides AD. Alpha-adrenergic vasoconstriction and nitroglycerin vasodilation of large coronary arteries in the conscious dog. Journal of Clinical Investigation 65: 5–14, 1980PubMedCrossRefGoogle Scholar
  74. Weidmann P, Gerber A, Mordasini R. Effects of antihypertensive therapy on serum lipoproteins. Hypertension 5 (Suppl. 3): III120–III131, 1983PubMedGoogle Scholar
  75. Weinberger M. Antihypertensive therapy and lipids: paradoxical influences on cardiovascular disease and risk. American Journal of Medicine 80 (Suppl. 2A): 64–70, 1986PubMedCrossRefGoogle Scholar
  76. Williams JF, Glick G, Braunwald E. Studies on cardiac dimensions in intact unanesthetized man. V. Effects of nitroglycerin. Circulation 32: 767–771, 1965PubMedCrossRefGoogle Scholar
  77. Young MA, Vatner SF. Regulation of large coronary arteries. Circulation Research 59: 579–596, 1986PubMedCrossRefGoogle Scholar

Copyright information

© ADIS Press Limited 1989

Authors and Affiliations

  • Eliot J. Lazar
    • 1
  • William H. Frishman
    • 1
  1. 1.Montefiore Medical CenterAlbert Einstein College of MedicineNew YorkUSA

Personalised recommendations